JP2022191301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022191301A5 JP2022191301A5 JP2022155470A JP2022155470A JP2022191301A5 JP 2022191301 A5 JP2022191301 A5 JP 2022191301A5 JP 2022155470 A JP2022155470 A JP 2022155470A JP 2022155470 A JP2022155470 A JP 2022155470A JP 2022191301 A5 JP2022191301 A5 JP 2022191301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- multiple myeloma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 208000034578 Multiple myelomas Diseases 0.000 claims 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 10
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 9
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 9
- 239000000611 antibody drug conjugate Substances 0.000 claims 9
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 9
- 101710112752 Cytotoxin Proteins 0.000 claims 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims 8
- 239000002619 cytotoxin Substances 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 229940044684 anti-microtubule agent Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229940126161 DNA alkylating agent Drugs 0.000 claims 2
- 239000012624 DNA alkylating agent Substances 0.000 claims 2
- 102000009572 RNA Polymerase II Human genes 0.000 claims 2
- 108010009460 RNA Polymerase II Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023184430A JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539825P | 2017-08-01 | 2017-08-01 | |
| US62/539,825 | 2017-08-01 | ||
| US201762596194P | 2017-12-08 | 2017-12-08 | |
| US62/596,194 | 2017-12-08 | ||
| JP2020505483A JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| PCT/IB2018/055753 WO2019025983A1 (en) | 2017-08-01 | 2018-07-31 | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Division JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023184430A Division JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022191301A JP2022191301A (ja) | 2022-12-27 |
| JP2022191301A5 true JP2022191301A5 (enExample) | 2023-05-29 |
| JP7377327B2 JP7377327B2 (ja) | 2023-11-09 |
Family
ID=63405281
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Active JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| JP2022155470A Active JP7377327B2 (ja) | 2017-08-01 | 2022-09-28 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| JP2023184430A Active JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Active JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023184430A Active JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10988546B2 (enExample) |
| EP (1) | EP3661963A1 (enExample) |
| JP (3) | JP7150820B2 (enExample) |
| KR (2) | KR102748628B1 (enExample) |
| CN (2) | CN117018219A (enExample) |
| AU (4) | AU2018311503C1 (enExample) |
| BR (1) | BR112020001989A2 (enExample) |
| CA (1) | CA3070539A1 (enExample) |
| CL (1) | CL2020000263A1 (enExample) |
| CO (1) | CO2020000772A2 (enExample) |
| CR (1) | CR20200100A (enExample) |
| EC (1) | ECSP20014523A (enExample) |
| IL (2) | IL312451A (enExample) |
| MA (1) | MA51447A (enExample) |
| MX (1) | MX2025001287A (enExample) |
| MY (1) | MY203183A (enExample) |
| PH (1) | PH12020500177A1 (enExample) |
| SG (1) | SG11202000499RA (enExample) |
| TW (2) | TWI815815B (enExample) |
| UA (1) | UA126813C2 (enExample) |
| WO (1) | WO2019025983A1 (enExample) |
| ZA (2) | ZA202001219B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3129406T (pt) * | 2014-04-11 | 2019-04-24 | Medimmune Llc | Compostos conjugados que compreendem anticorpos com manipulação de cisteínas |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2019025983A1 (en) * | 2017-08-01 | 2019-02-07 | Medimmune, Llc | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AU2020228367A1 (en) * | 2019-02-26 | 2021-10-14 | Vivasor, Inc. | Antigen binding proteins that bind BCMA |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| MX2021013391A (es) * | 2019-05-03 | 2022-01-26 | Celgene Corp | Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo. |
| US20220362394A1 (en) * | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| UY38700A (es) * | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| PH12021552986A1 (en) * | 2019-05-31 | 2023-08-14 | Dana Farber Cancer Inst Inc | Combination therapy |
| BR112022001546A2 (pt) * | 2019-07-30 | 2022-03-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| CN115279781B (zh) * | 2020-03-26 | 2025-05-09 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN116096752B (zh) * | 2020-06-05 | 2025-10-28 | 卫材R&D管理有限公司 | 抗bcma抗体-药物缀合物及其使用方法 |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| WO2022097047A1 (en) * | 2020-11-04 | 2022-05-12 | Medimmune, Llc | Treatment methods using anti-bcma antibody-drug conjugates |
| CN114763383B (zh) * | 2021-01-13 | 2024-12-17 | 博生吉医药科技(苏州)有限公司 | 靶向人bcma的单克隆抗体及其应用 |
| CN112812185B (zh) * | 2021-02-08 | 2022-01-18 | 华道(上海)生物医药有限公司 | 一种抗b细胞成熟抗原的单克隆抗体及其应用 |
| CA3210069A1 (en) * | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
| US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
| CN116745325A (zh) * | 2021-08-16 | 2023-09-12 | 上海优替济生生物医药有限公司 | Bcma靶向抗体、嵌合抗原受体及其应用 |
| CA3236930A1 (en) * | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117164714B (zh) * | 2023-10-08 | 2024-04-23 | 北京奇迈永华生物科技有限公司 | 一种靶向bcma的抗体及其应用 |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119841951B (zh) * | 2024-12-25 | 2025-10-14 | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 一种抗bcma抗体或其抗原结合片段及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| WO2004005326A2 (de) | 2002-07-09 | 2004-01-15 | Morphochem Aktiengellschaft Fu | Tubulysinkonjugate |
| WO2004005327A1 (de) | 2002-07-09 | 2004-01-15 | Morphochem Ag Komb Chemie | Neue tubulysinanaloga |
| DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
| US20110263650A1 (en) | 2007-07-20 | 2011-10-27 | Helmholtz-Zentrum Für Infektions-Forschung Gmbh | Tubulysin D Analogues |
| WO2009134279A1 (en) | 2007-07-20 | 2009-11-05 | The Regents Of The University Of California | Tubulysin d analogues |
| WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
| HRP20161194T1 (hr) * | 2009-03-10 | 2016-11-04 | Biogen Ma Inc. | Anti-bcma protutijela |
| MX2013001402A (es) | 2010-08-06 | 2013-08-29 | Endocyte Inc | Proceso para preparar tubulisinas. |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015155345A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| TW201625662A (zh) | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物 |
| EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
| US20190209704A1 (en) * | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| PT3337824T (pt) * | 2015-08-17 | 2020-09-10 | Janssen Pharmaceutica Nv | Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações |
| WO2019025983A1 (en) | 2017-08-01 | 2019-02-07 | Medimmune, Llc | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
| PH12021552986A1 (en) * | 2019-05-31 | 2023-08-14 | Dana Farber Cancer Inst Inc | Combination therapy |
-
2018
- 2018-07-31 WO PCT/IB2018/055753 patent/WO2019025983A1/en not_active Ceased
- 2018-07-31 EP EP18760047.3A patent/EP3661963A1/en active Pending
- 2018-07-31 CR CR20200100A patent/CR20200100A/es unknown
- 2018-07-31 TW TW107126542A patent/TWI815815B/zh active
- 2018-07-31 MA MA051447A patent/MA51447A/fr unknown
- 2018-07-31 KR KR1020207005140A patent/KR102748628B1/ko active Active
- 2018-07-31 TW TW112131870A patent/TWI881438B/zh active
- 2018-07-31 JP JP2020505483A patent/JP7150820B2/ja active Active
- 2018-07-31 CA CA3070539A patent/CA3070539A1/en active Pending
- 2018-07-31 KR KR1020247042931A patent/KR20250009550A/ko active Pending
- 2018-07-31 MY MYPI2020000524A patent/MY203183A/en unknown
- 2018-07-31 UA UAA202000974A patent/UA126813C2/uk unknown
- 2018-07-31 AU AU2018311503A patent/AU2018311503C1/en active Active
- 2018-07-31 IL IL312451A patent/IL312451A/en unknown
- 2018-07-31 CN CN202311040626.0A patent/CN117018219A/zh active Pending
- 2018-07-31 CN CN201880049730.7A patent/CN110997721B/zh active Active
- 2018-07-31 BR BR112020001989-5A patent/BR112020001989A2/pt unknown
- 2018-07-31 IL IL272304A patent/IL272304B2/en unknown
- 2018-07-31 SG SG11202000499RA patent/SG11202000499RA/en unknown
- 2018-07-31 US US16/050,944 patent/US10988546B2/en active Active
-
2020
- 2020-01-23 CO CONC2020/0000772A patent/CO2020000772A2/es unknown
- 2020-01-24 PH PH12020500177A patent/PH12020500177A1/en unknown
- 2020-01-28 MX MX2025001287A patent/MX2025001287A/es unknown
- 2020-01-30 CL CL2020000263A patent/CL2020000263A1/es unknown
- 2020-02-26 ZA ZA2020/01219A patent/ZA202001219B/en unknown
- 2020-02-27 EC ECSENADI202014523A patent/ECSP20014523A/es unknown
-
2021
- 2021-03-29 US US17/215,479 patent/US11912782B2/en active Active
- 2021-08-25 ZA ZA2021/06131A patent/ZA202106131B/en unknown
-
2022
- 2022-03-01 AU AU2022201397A patent/AU2022201397B2/en active Active
- 2022-09-28 JP JP2022155470A patent/JP7377327B2/ja active Active
-
2023
- 2023-10-27 JP JP2023184430A patent/JP7754906B2/ja active Active
-
2024
- 2024-01-17 US US18/414,892 patent/US20240294666A1/en active Pending
- 2024-02-09 AU AU2024200847A patent/AU2024200847B2/en active Active
-
2025
- 2025-05-06 AU AU2025203224A patent/AU2025203224A1/en not_active Abandoned